Advances in the pharmacological treatment of pathological gambling

Journal of Gambling Studies

Volumn 19, Issue 1, 2003, Pages 85-109

  Grant, Jon E ^a,c   Suck, Won Kim ^a   Potenza, Marc N ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b YALE UNIVERSITY   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Impulse control; Pathological gambling; Psychopharmacology

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; LITHIUM; MU OPIATE RECEPTOR; NALTREXONE; NEUROLEPTIC AGENT; OPIATE ANTAGONIST; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID; NARCOTIC ANTAGONIST; TRANQUILIZER;

BEHAVIORAL SCIENCE; CLINICAL FEATURE; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDICAL SOCIETY; META ANALYSIS; PATHOLOGICAL GAMBLING; PATIENT COMPLIANCE; PRACTICE GUIDELINE; REVIEW; SCORING SYSTEM; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT WITHDRAWAL; ADDICTION; DRUG ADMINISTRATION;

ANTIMANIC AGENTS; BEHAVIOR, ADDICTIVE; DRUG ADMINISTRATION SCHEDULE; GAMBLING; HUMANS; NARCOTIC ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 0037365675     PISSN: 10505350     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1021227214142     Document Type: Review

References (107)

1. Albanese, M.J., Khantzian, E.J., Murphy, S.L., & Green, A.I. (1994). Decreased substance use in chronically psychotic patients treated with clozapine. American Journal of Psychiatry, 151, 780-781. [Letter].
2. American Psychiatric Association Committee on Nomenclature and Statistics. (1980). Diagnostic and statistical manual of mental disorders (3rd Ed.). Washington, D.C.: American Psychiatric Association.
3. American Psychiatric Association Committee on Nomenclature and Statistics. (1987). Diagnostic and statistical manual of mental disorders (3rd Ed.-Revised). Washington, D.C.: American Psychiatric Association.
4. th Ed.-Text Revision). Washington, D.C.: American Psychiatric Association.
5. Barrett, R.P., Feinstein, C., & Hole, W.T. (1989). Effects of naloxone and naltrexone on self-injury: a double-blind, placebo-controlled analysis. American Journal of Mental Retardation, 93, 644-651.
6. Blanco, C., Moreyra, P., Nunes, E.V., Sáiz-Ruiz, J., & Ibánez, A. (2001). Pathological gambling: addiction or compulsion? Seminars in Clinical Neuropsychiatry, 6, 167-176.
7. Blanco, C., Orensanz-Munoz, L., Blanco-Jerez, C., & Saiz-Ruiz, J. (1996). Pathological gambling and platelet MAO activity: a psychobiological study. American Journal of Psychiatry, 153, 119-121.
8. Blanco, C., Petkova, E., Ibanez, A., & Sáiz-Ruiz, J. (2002). A pilot placebo-controlled study of fluvoxamine for pathological gambling. Annals of Clinical Psychiatry, 14, 9-15.
9. Broekkamp, C.L. & Phillips, A.G. (1979). Facilitation of self-stimulation behavior following in tracerebral microinjections of opioids into the ventral tegmental area. Pharmacology Biochemistry and Behavior, 11, 289-295.
10. Buckley, P., Thompson, P., Way, L., & Meltzer, H.Y. (1994). Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy. American Journal of Psychiatry, 151, 385-389.
11. Carrasco, J.L., Saiz-Ruiz, J., Hollander, E., Cesar, J., & Lopez-Ibor Jr., J.J. (1994). Low platelet monoamine oxidase activity in pathological gambling. Acta Psychiatrica Scandinavia, 90, 427-31.
12. Carroll, K.M., Ball, S.A., Nich, C., O'Connor, P.G., Eagan, D.A., Frankfurter, T.L., Triffleman, E.G., Shi, J., & Rounsaville, B.J. (2001). Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence. Archives of General Psychiatry, 58, 755-761.
13. Chambers, R.A., Krystal, J. H., & Self, D.W. (2001). A neurobiological basis for substance abuse comorbidity in schizophrenia. Biological Psychiatry, 50, 71-83.
14. Chambers, R.A. & Potenza, M.N. (2001). Schizophrenia and pathological gambling. American Journal of Psychiatry, 158, 497-498. [Letter].
15. Chambers, R.A. & Potenza, M.N. (in press). Impulse control disorders. In M.J. Adinoff & R.B. Daroff (Eds.), The encyclopedia of neurological sciences. San Diego, California: Academic Press.
16. Crockford, D.N. & el-Guebaly, N. (1998). Naltrexone in the treatment of pathological gambling and alcohol dependence. Canadian Journal of Psychiatry, 43, 86. [Letter].
17. Cunningham-Williams, R.M. & Cottler, L.B. (2001). The epidemiology of pathological gambling. Seminars in Clinical Neuropsychiatry, 6:155-166.
18. rd, & Spitznagel, E.L. (1998). Taking chances: problem gamblers and mental health disorders - results from the St. Louis Epidemiologic Catchment Area Study. American Journal of Public Health. 88:1093-1096.
19. Daly, K.A. & Fatemi, S.H. (1999). Lamotrogine and impulse behavior. Canadian Journal of Psychiatry, 44, 395-396. [Letter].
20. Davidson, D., Swift, R.M., &: Fitz, E. (1996). Naltrexone increases the latency to drink in social drinkers. Alcoholism and Clinical Experimental Research, 20, 732-739.
21. DeCaria, C.M., Begaz, T., & Hollander, E. (1998). Serotonergic and noradrenergic function in pathological gambling. CNS Spectrums, 3, 38-47.
22. DeCaria, C.M., Hollander, E., Grossman, R., Wong, C.M., Mosovich, S.A., & Cherkasky, S. (1996). Diagnosis, neurobiology, and treatment of pathological gambling. Journal of Clinical Psychiatry, 57 (S8), 80-83.
23. De la Gandara, J.J. (1999). Fluoxetine: open-trial in pathological gambling. Presented at the 152nd Annual Meeting of the American Psychiatric Association; May 16-21; Washington, DC. [Abstract].
24. Farren, C.K., Rezvani, A.H., Overstreet, D., & O'Malley, S. (2000). Combination pharmacotherapy in alcoholism: a novel treatment approach. CNS Spectrums, 5, 70-76.
25. Feeney, D.J. & Klykylo, W.M. (1997). Treatment for kleptomania. Journal of the American Academy of Child & Adolescent Psychiatry, 36, 723-724.
26. Gardell, L.R., Reid, L.D., Boedeker, K.L., Liakos, T.M., & Hubbell, C.L. (1997a). Isradipine and naltrexone in combination with isradipine interact with a period of abstinence to reduce rats' intakes of an alcoholic beverage. Alcoholism and Clinical Experimental Research, 21, 1592-1598.
27. Gardell, L.R., Whalen, C.A., Chattophadyay, S., Cavallaro, C.A., Hubbell, C.L., & Reid, L.D. (1997b). Combination of naltrexone and fluoxetine on rats' propensity to take alcoholic beverage. Alcoholism and Clinical Experimental Research, 21, 1435-1439.
28. George, T.P. & Krystal, J.H. (2000). Comorbidity of psychiatric and substance abuse disorders. Current Opinion in Psychiatry, 13, 327-331.
29. George, T.P., Ziedonis, D.M., Feingold, A., Pepper, W.T., Satterburg, C.A., Winkel, J., Rounsaville, B. J., & Kosten, T.R. (2000). Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. American Journal of Psychiatry, 157, 1835-1842.
30. Gerstein, D., Hoffmann, J., Larison, C., Engelman, L., Murphy, S., Palmer, A., Chuchro, L., Toce, M., Johnson, R., Buie, T., & Hill, M.A. (1999). Gambling impact and behavior study. National Opinion Research Center, University of Chicago. http://www.norc.uchicago.edu/new/gambfin.htm".
31. Goodman, W.K., McDougle, C.J., Price, L.H., Riddle, M.A., Pauls, D.L., & Leckman, J.F. (1990). Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive-compulsive disorder? Journal of Clinical Psychiatry, 51, 36-43.
32. Goodwill, F.K & Jamison, K.R. (1990). Manic-depressive illness. New York City, NY: Oxford University Press.
33. Grant, J.E. & Kim, S.W. (2001a). Demographic and clinical features of 131 adult pathological gamblers. Journal of Clinical Psychiatry, 62, 957-962.
34. Grant, J.E. & Kim, S.W. (2001b). Pharmacotherapy of pathological gambling disorder. Psychiatric Annals, 32, 161-170.
35. Grant, J.E. & Kim, S.W. (2002). An open label study of naltrexone in the treatment of kleptomania. Journal of Clinical Psychiatry, 63, 349-356.
36. Guy, W. (1976). ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health, 218-222.
37. Haller, R. & Hinterhuber, H. (1994). Treatment of pathological gambling with carbamazepine. Pharmacopsychiatry, 27, 129.
38. th Annual Meeting of the Society for Research of Nicotine and Tobacco. [Abstract].
39. Hollander, E. (2001). "Very bad behaviors" in the Symposium "The impulsive aggressive spectrum: Challenging populations." Presented at the 154th Annual Meeting of the American Psychiatric Association; May 7 and 8; New Orleans, LA. [Abstract].
40. Hollander, E., DeCaria, C.M., Finkell, J.N., Begaz, T., Wong, C.M., & Cartwright, C. (2000). A randomized double-blind fluvoxamine/placebo crossover trial in pathological gambling. Biological Psychiatry, 47, 813-817.
41. Hollander, E., DeCaria, C.M., Mari, E., Wong, C.M., Mosovich, S., Grossman, R., & Begaz, T. (1998). Short-term single-blind fluvoxamine treatment of pathological gambling. American Journal of Psychiatry, 155, 1781-1783.
42. Hollander, E., Frenkel, M., DeCaria, C., Trungold, S., & Stein, D.J. (1992). Treatment of pathological gambling with clomipramine. American Journal of Psychiatry, 149, 710-711. [Letter].
43. Hollander, E. & Wong, C.M. (1995). Obsessive-compulsive spectrum disorders. Journal of Clinical Psychiatry, 56(S4), 3-6.
44. Hollister, L., Schwin, R.L., & Kasper, P. (1977). Naltrexone treatment of opiate-dependent persons. Drug and Alcohol Dependence, 2, 203-209.
45. Holmes, E.K., Mateczun, J.M., Lall, R., Wilcove, G.L. (1998). Pilot study of suicide risk factors among personnel in the United States Marine Corps (Pacific Forces). Psychological Reports, 83, 3-11.
46. Jaffe, A.J., Rounsaville, B., Chang, G., Shottenfeld, R.S., Meyer, R.E., & O'Malley, S.S. (1996). Naltrexone, relapse prevention and supportive therapy with alcoholics: an analysis of patient matching. Journal of Consulting Clinical Psychology, 64, 1044-1053.
47. Kane, J., Honigfeld, G., Singer, J, & Meltzer, H. (1988). Clozapine for the treatment-resistant schizophrenic: a double blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789-796.
48. Kapur, S. (1998). A new framework for investigating antipsychotic action in humans: lessons from PET imaging. Molecular Psychiatry, 3, 135-140.
49. Kim, S.W. (1998). Opioid antagonists in the treatment of impulse control disorders. Journal of Clinical Psychiatry, 59, 159-164.
50. Kim, S.W. & Grant, J.E. (2001a). An open naltrexone treatment study of pathological gambling disorder. International Clinical Psychopharmacology, 16, 285-289.
51. Kim, S.W. & Grant, J.E. (2001b). The psychopharmacology of pathological gambling. Seminars in Clinical Neuropsychiatry, 6, 184-194.
52. Kim, S.W. & Grant, J.E. (2001c). Personality dimensions in pathological gambling disorder and obsessive compulsive disorder. Psychiatry Research, 104, 205-212.
53. Kim, S.W., Grant, J.E., Adson, D.E., & Remmel, R.P. (2001a). A preliminary report on a possible naltrexone and nonsteroidal analgesics interaction. Journal of Clinical Psychopharmacology, 21, 632-634. [Letter].
54. Kim, S.W., Grant, J.E., Adson, D.E., & Shin, Y.C. (2001b). Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biological Psychiatry, 49, 914-921.
55. Kim, S.W., Grant, J.E., Adson, D.E., Shin, Y.C., & Zaninelli, R.M. (2002). A double-blind, placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. Journal of Clinical Psychiatry, 63, 501-507.
56. Ladouceur, R., Boisvert, J.M., &: Dumont, J. (1994). Cognitive-behavioral treatment for adolescent pathological gamblers. Behavior Modification, 18, 230-242.
57. Lesieur, H.R. & Rosenthal, R.J. (1991). Pathological gambling: a review of the literature (prepared for the American Psychiatric Association Task Force of DSM-IV Committee on Disorders of Impulse Control Not Elsewhere Classified). Journal of Gambling Studies, 7, 5-39.
58. Mason, B.J. & Ownby, R.L. (2000). Acamprosate for the treatment of alcohol dependence: a review of double-blind, placebo-controlled trials. CNS Spectrums, 5, 58-69.
59. Martin, A., Scahill, L., Vitulano, L., & King, R.A. (1998). Stimulant use and trichotillomania. Journal of the American Academy of Child & Adolescent Psychiatry, 37, 349-50.
60. Matthews, R.T. & German, D.C. (1984). Electrophysiological evidence for excitation of rat ventral tegmental area dopamine neurons by morphine. Neuroscience, 11, 617-625.
61. McDougle, C.J., Epperson, C.N., Pelton, G.H., Wasylink, S., & Price, L.H. (2000). A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Archives of General Psychiatry, 57, 794-801.
62. McDougle, C.J., Goodman, W.K., Leckman, J.F., Lee, N.C., Heninger, G.R., & Price, L.H. (1994). Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics. Archives of General Psychiatry, 51, 302-308.
63. McElroy, S.L., Hudson, J.I., Phillips, K.A., Keck, P.E., & Pope, H.G. (1993). Clinical and theoretical implications of a possible link between obsessive-compulsive and impulse control disorders. Depression, 1, 121-132.
64. McElroy, S.L., Pope, H.G. Jr., Keck, P.E., Hudson, J.I., Phillips, K.A., & Strakowski, S.M. (1996). Are impulse-control disorders related to bipolar disorder? Comprehensive Psychiatry, 37, 229-240.
65. McLellan, A.T., Arndt, I.O., Metzger, D.S., Woody, G.E., & O'Brien, C.P. (1993). The effects of psychosocial services in substance abuse treatment. Journal of the American Medical Association, 269, 1953-1959.
66. Meltzer, H. Y. (1995). Atypical antipsychotic drugs. In F.E. Bloom & D.J. Kupfer (Eds), Neuropsychopharmacology: the fourth generation of progress. New York: D.J. Raven Press.
67. Meltzer, H. Y. (1999). The role of serotonin in antipsychotic drug action. Neuropsychopharmacology, 21, 106S-115S.
68. Mitchell, J.E., Morley, J.E., Levine, A.S., Hatsukami, D., Gannon, M., & Pfohl, D. (1987). High-dose naltrexone therapy and dietary counseling for obesity. Biological Psychiatry, 22, 35-42.
69. Monti, P.M, Rohsenow, D.J., Hutchison, K., Swift, R.M., Mueller, T.I., Colby, S.M., Brown, R.A., Gulliver, S.B., Gordon, A., & Abrams, D.B. (1999). Naltrexone's effect on cue-elicited craving among alcoholics in treatment. Alcoholism and Clinical Experimental Research, 23, 1386-1394.
70. Monti, P.M, Rohsenow, D.J., Swift, R.M., Abrams, D.B., Colby, S.M., & Mueller, T.I. (1996). Effect of naltrexone on urge to drink during alcohol cue exposure: preliminary results. Alcoholism and Clinical Experimental Research, 20, 92A.
71. Moskowitz, J.A. (1980). Lithium and lady luck: use of lithium carbonate in compulsive gambling. New York State Journal of Medicine, 80, 785-788.
72. Nordin, C. & Eklundh, T. (1999). Altered CSF 5-HIAA disposition in pathologic male gamblers. CNS Spectrums, 4, 25-33.
73. O'Brien, C.P. (1997). A range of research-based pharmacotherapies for addiction. Science, 278, 66-70.
74. O'Malley, S.S., Jaffe, A.J., Chang, G., Schottenfeld, R.S., Meyer, R.E., & Rounsaville, B.J. (1992). Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Archives of General Psychiatry, 49, 881-887.
75. Pallanti, S., Quercioli, L., Sood, E., & Hollander E. (2002). Lithium and valproate treatment of pathological gambling: a randomized single-blind study. Journal of Clinical Psychiatry, 63, 559-564.
76. Petry, N.M. &: Armentano, C. (1999). Prevalence, assessment, and treatment of pathological gambling: a review. Psychiatric Services, 50, 1021-1027.
77. Petry, N.M. & Roll, J.M. (2001). A behavioral approach to understanding and treating pathological gambling. Seminars in Clinical Neuropsychiatry, 6, 177-183.
78. Phillips, A.G. & LePiane, F.G. (1980). Reinforcing effects of morphine microinjection onto the ventral tegmental area. Pharmacology Biochemistry and Behavior, 12, 965-968.
79. Phillips, D.P., Welty, W.R., & Smith, M.M. (1997). Elevated suicide levels associated with legalized gambling. Suicide and Life Threatening Behavior, 27, 373-378.
80. th Ed. Medical Economics Company. Montvale, NJ.
81. Potenza, M.N. (2001). The neurobiology of pathological gambling. Seminars in Clinical Neuropsychiatry, 6, 217-226.
82. Potenza, M.N. (2002). A perspective on future directions in the prevention, treatment and research of pathological gambling. Psychiatric Annals, 32, 203-207.
83. Potenza, M.N., Fiellin, D.A., Heninger, G.R., Rounsaville, B.J., & Mazure, C.M. (2002). Gambling: an addictive behavior with primary care implications. Journal of General Internal Medicine, 17, 1-12.
84. Potenza, M.N. & Hollander, E. (2002). Pathological gambling and impulse control disorders. In J. Coyle, C. Nemeroff, D. Charney, &: K. Davis (Eds), Neuropsychopharmacology: the 5th generation of progress (pp. 1725-1741). Baltimore, MD: Lippincott Williams and Wilkens.
85. Potenza, M.N., Kosten, T.R., & Rounsaville, B.J. (2001). Pathological gambling. Journal of the American Medical Association, 286, 141-144.
86. Potenza, M.N. & McDougle, C.J. (1998). Potential of atypical antipsychotics in the treatment of non-psychotic disorders. CNS Drugs, 9, 213-232.
87. Potenza, M.N., Steinberg, M.A., McLaughlin, S.D., Wu, R., Rounsaville, B.J., & O'Malley, S.S. (2000). Illegal behaviors in problem gambling: analysis of data from a gambling helpline. Journal of the American Academy of Psychiatry and the Law, 28, 389-403.
88. Roth, A.S., Ostroff, R.B., & Hoffman, R.E. (1996). Naltrexone as a treatment for repetitive self-injurious behaviour: an open-label trial. Journal of Clinical Psychiatry, 57, 233-237.
89. Rounsaville, B.J. (1995). Can psychotherapy rescue naltrexone treatment of opioid addiction? In L.S. Onken & J.D. Blaine (Eds.), Potentiating the effects of medications. Rockville, Maryland: National Institute on Drug Abuse Research Monograph, 105, 37-52.
90. Rugle, L. (2000). The use of olanzapine in the treatment of video poker pathological gamblers. Presented at the conference entitled, "The Comorbidity of Pathological Gambling: A Current Research Synthesis"; December 3-5; Las Vegas, Nevada. [Abstract].
91. Saxena, S., Wang, D., Bystritsky, A., & Baxter, L.R. (1996). Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. Journal of Clinical Psychiatry, 57, 303-306.
92. Seeman, P. (1992). Dopamine receptor sequences: therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology, 7, 261-284.
93. Shaffer, H.J. & Hall, M.N. (1996). Estimating the prevalence of adolescent gambling disorders: a quantitative synthesis and guide toward standard gambling nomenclature. Journal of Gambling Studies, 12, 193-214.
94. Shaffer, H.J., Hall, M.N., & Vander Bilt, J. (1999). Estimating the prevalence of disordered gambling behavior in the United States and Canada: a research synthesis. American Journal of Public Health, 89, 1369-1376.
95. Shinohara, K., Yanagisawa, A., Kagota, Y., Gomi, A., Nemoto, K., Moriya, E., Furusawa, E., Furuya, K., & Tersawa, K. (1999). Physiological changes in Pachinko players; beta-endorphin, catecholamines, immune system substances and heart rate. Applied Human Science, 18, 37-42.
96. Stein, D.J., Bouwer, M.B., Hawkridge, S., & Emsley, R.A. (1997). Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. Journal of Clinical Psychiatry, 58, 119-122.
97. Stewart, J. (1984). Reinstatement of heroin and cocaine self-administration behavior in the rat by intracerebral application of morphine in the ventral tegmental area. Pharmacology Biochemistry and Behavior, 20, 917-923.
98. Sutherland, G., Stapleton, J.A., Russell, M.A.H., & Feyerabend, C. (1995). Naltrexone, smoking behaviour and cigarette withdrawal. Psychopharmacology, 120, 418-425.
99. Swift, R.M. (2000). Opioid antagonists and alcoholism treatment. CNS Spectrums, 5, 49-57.
100. Sylvain, C., Ladouceur, R., & Boisvert, J.M. (1997). Cognitive and behavioral treatment of pathological gambling: a controlled study. Journal of Consulting and Clinical Psychology, 65, 727-732.
101. van Wolfswinkel, L. & van Ree, J.M. (1985). Effects of morphine and naloxone on thresholds of ventral tegmental electrical self-stimulation. Naunyn-Schmiedebergs Archives of Pharmacology, 330, 84-92.
102. Verebey, K.G. & Mule, S.J. (1985). Naltrexone (Trexan): a review of hepatotoxicity issues. NIDA Research Monograph, 67, 73-81.
103. Volkow, N.D., & Fowler, J.S. (2000). Addiction, a disease of compulsion and drive: Involvement of the orbitofrontal cortex. Cerebral Cortex, 10, 318-325.
104. Volpicelli, J.R., Alterman, A.I., Hayashida, M., & O'Brien, C.P. (1992). Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry, 49, 876-880.
105. Volpicelli, J.R., Rhines, K.C., Rhines, J.S., Volpicelli, L.A., Alterman, A.I., & O'Brien, C.P. (1997). Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry, 54, 737-742.
106. Walters, A.S., Barrett, R.P., Feinstein, C., Mercurio, A., & Hole, W.T. (1990). A case report of naltrexone treatment of self-injury and social withdrawal in autism. Journal of Autism and Developmental Disorders, 20, 169-176.
107. Zimmerman, M. & Breen, R. (2002). An open-label study of citalopram in the treatment of pathological gambling. Journal of Clinical Psychiatry, 63, 44-48.